Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms.

Chromy, Brett A; Elsheikh, Maher; Christensen, Tova L; Livingston, Doug; Petersen, Kyle; Bearinger, Jane P; Hoeprich, Paul D

Chromy, Brett A; Elsheikh, Maher; Christensen, Tova L; Livingston, Doug; Petersen, Kyle; Bearinger, Jane P; Hoeprich, Paul D.

Affiliation

Chromy BA; University of California Davis School of Medicine, Department of Pathology & Laboratory Medicine, Davis, CA 95616, USA. brett.chromy@ucdmc.ucdavis.edu

Future Microbiol ; 7(8): 1011-20, 2012 Aug.

Article in En | MEDLINE | ID: mdl-22913359

Subject(s)

Anti-Bacterial Agents/pharmacology; Bacteria/drug effects; Drug Resistance, Multiple, Bacterial; Rifamycins/pharmacology; Bacteria/growth & development; Bacteria/metabolism; Drug Evaluation, Preclinical/methods; Humans; Microbial Sensitivity Tests

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifamycins / Bacteria / Drug Resistance, Multiple, Bacterial / Anti-Bacterial Agents Limits: Humans Language: En Journal: Future Microbiol Journal subject: MICROBIOLOGIA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google